Cingulate Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Cingulate Inc. (CING) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$1.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-08-13
- Cingulate Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for the quarter ending 2026-06-30 was -$1.23M.
- Cingulate Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for the quarter ending 2026-03-31 was -$1.96M.
- Cingulate Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for the quarter ending 2025-09-30 was -$1.54M.
- Cingulate Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for the quarter ending 2025-06-30 was -$1.04M.
- Cingulate Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$4.71M.
- Cingulate Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$3.48M.
- Cingulate Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$4.94M.
- Cingulate Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$3.71M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 3 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 3 month as first filed | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 6 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 6 month as first filed | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 9 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 9 month as first filed | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.23M 10-Q · filed 2026-08-13 | -$3.19M 10-Q · filed 2026-08-13 | ||||||
| 2026-03-31 | -$1.96M 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | -$4.71M 10-K · filed 2026-03-18 | |||||||
| 2025-09-30 | -$1.54M 10-Q · filed 2025-11-13 | -$3.40M 10-Q · filed 2025-11-13 | ||||||
| 2025-06-30 | -$1.04M 10-Q · filed 2026-08-13 | -$1.00M 10-Q · filed 2025-08-19 | -$1.85M 10-Q · filed 2026-08-13 | -$1.80M 10-Q · filed 2025-08-19 | ||||
| 2025-03-31 | -$809.07K 10-Q · filed 2026-05-14 | -$798.58K 10-Q · filed 2025-05-08 | ||||||
| 2024-12-31 | -$3.48M 10-K · filed 2026-03-18 | -$3.26M 10-K · filed 2025-03-27 | ||||||
| 2024-09-30 | -$866.39K 10-Q · filed 2025-11-13 | -$678.64K 10-Q · filed 2024-11-07 | -$2.17M 10-Q · filed 2025-11-13 | -$1.98M 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | -$709.99K 10-Q · filed 2025-08-19 | -$1.30M 10-Q · filed 2025-08-19 | ||||||
| 2024-03-31 | -$588.27K 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | -$4.94M 10-K · filed 2025-03-27 | |||||||
| 2023-09-30 | -$1.26M 10-Q · filed 2024-11-07 | -$3.49M 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | -$1.39M 10-Q · filed 2024-08-13 | -$2.23M 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | -$841.03K 10-Q · filed 2024-05-08 | |||||||
| 2022-12-31 | -$3.71M 10-K · filed 2024-04-01 | |||||||
| 2022-09-30 | -$845.72K 10-Q · filed 2023-11-13 | -$2.73M 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | -$848.48K 10-Q · filed 2023-08-14 | -$1.89M 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | -$1.04M 10-Q · filed 2023-05-10 | |||||||
| 2021-12-31 | -$563.52K 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |